Literature DB >> 17303011

Antisense oligonucleotides targeting midkine inhibit tumor growth in an in situ human hepatocellular carcinoma model.

Li-Cheng Dai1, Xiang Wang, Xing Yao, Li-Shan Min, Jin-Liang Ping, Jian-Fang He.   

Abstract

AIM: To evaluate the in vivo antitumor effects of antisense oligonucleotides targeting midkine (MK-AS).
METHODS: An in situ human hepatocellular carcinoma (HCC) model was established in mice livers orthotopically. The MK-AS and 5- fluorouracil (5-Fu) were administered intravenously. The tumor sizes and plasma alpha-fetoprotein (AFP) were measured by calipers and radiation immunoassay respectively. The morphology of tumors was evaluated by hematoxylin-eosin staining of histological sections. Human MK, p53, Bax, Bcl-2, and caspase-3 protein content were detected by Western blotting.
RESULTS: MK-AS significantly inhibited in situ human HCC growth in mice compared with the saline group in a dose-dependent manner. After the treatment with MK-AS or with 5-Fu, the plasma AFP concentration decreased in a dose-dependent manner. Interestingly, MK-AS also clearly downregulated the protein level of Bcl-2, and upregulated p53, Bax, and caspase-3 in the hepatocellular carcinoma tissue.
CONCLUSION: These results demonstrated that MK-AS was an effective antitumor antisense oligonucleotide in vivo in mice; its antitumor effect is associated with the increase of pro-apoptotic proteins, such as p53, Bax, and caspase-3, and the decrease of the anti-apoptotic protein, Bcl-2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303011     DOI: 10.1111/j.1745-7254.2007.00532.x

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  8 in total

1.  Promotion of self-renewal of embryonic stem cells by midkine.

Authors:  Xing Yao; Zhou Tan; Bin Gu; Rong-rong Wu; Yu-kan Liu; Li-cheng Dai; Ming Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-05       Impact factor: 6.150

Review 2.  Involvement of midkine in neuroblastoma tumourigenesis.

Authors:  S Kishida; K Kadomatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  Inhibitory effect of midkine-binding peptide on tumor proliferation and migration.

Authors:  Hui-Lian Huang; Jian-Fen Shen; Li-Shan Min; Jin-Liang Ping; Yong-Liang Lu; Li-Cheng Dai
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

4.  Midkine inhibitors: application of a simple assay procedure to screening of inhibitory compounds.

Authors:  Takashi Matsui; Keiko Ichihara-Tanaka; Chen Lan; Hisako Muramatsu; Toshiharu Kondou; Chizuru Hirose; Sadatoshi Sakuma; Takashi Muramatsu
Journal:  Int Arch Med       Date:  2010-06-21

5.  Effects of human midkine on spontaneous resorption of herniated intervertebral discs.

Authors:  Guoshun Zhou; Licheng Dai; Xuesheng Jiang; Zhihong Ma; Jinliang Ping; Jianyou Li; Xiongfeng Li
Journal:  Int Orthop       Date:  2009-03-11       Impact factor: 3.075

6.  Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

7.  In vitro and in vivo suppression of hepatocellular carcinoma growth by midkine-antisense oligonucleotide-loaded nanoparticles.

Authors:  Li-Cheng Dai; Xing Yao; Xiang Wang; Shu-Qiong Niu; Lin-Fu Zhou; Fang-Fang Fu; Shui-Xin Yang; Jin-Liang Ping
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

8.  Midkine confers Adriamycin resistance in human gastric cancer cells.

Authors:  Ying-ying Xu; Xiao-yun Mao; Yong-xi Song; Feng Zhao; Zhen-ning Wang; Wei-xu Zhang; Hui-mian Xu; Feng Jin
Journal:  Tumour Biol       Date:  2012-05-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.